Eureka Home »
Welcome to Eureka, an online community for scientists to explore, connect and share big ideas.
Meeting the challenges of antibody-dependent cellular phagocytosis with more reliable assays. The second of our three-part series.
Antibody-mediated cellular phagocytosis is often overlooked in analyzing biologics. Find out why in the first of our three-part series about this neglected mechanism of action.
In silico simulations and the new paradigm in cardiac toxicity testing.
Getting a novel drug to market is a bit like finishing first in the Boston marathon. It's the ultimate victory in a long, expensive journey. The question is: How many can actually do it?
Biomedical manufacturers and conservationists alike have a vested interest in making sure the Atlantic horseshoe crab, whose ancestry dates back some 440 million years, flourishes.
Tiered approaches have been used in method validation for decades, but to what level CROs are using them in the preclinical arena—particularly early discovery—is difficult to say.
My top priority is the horseshoe crab, a sea creature of little interest in culinary circles but uniquely valuable to biomedical research.
The up and coming strategy called CiPA will allow us to know more about the potential liabilities of test articles before the start of a large animal telemetry study, but in practice, such information will have little impact on the design and conduct of in vivo safety pharmacology studies. Here's why.
Stem-cell derived human cardiomyocytes are commercially available in sufficient enough quantities to be practical for routine safety pharmacology studies.
Minipigs have been used extensively in dermal studies but the diminutive swine's role in animal research is expanding.